本文選題：胃癌　切入點(diǎn)：RhoA　出處：《濟(jì)南大學(xué)》2017年碩士論文

【摘要】：目的:檢測(cè)胃癌(GC)組織中RhoA的表達(dá)情況,分析其在GC組織中的表達(dá)及其意義;結(jié)合隨訪資料進(jìn)行生存分析,探討RhoA與GC患者預(yù)后和生存的關(guān)系。方法:收集山東省醫(yī)學(xué)科學(xué)院附屬醫(yī)院89例保存完好的術(shù)后胃癌組織石蠟標(biāo)本為研究對(duì)象,用免疫組化方法檢測(cè)RhoA在胃癌的表達(dá),分析RhoA的表達(dá)與臨床病理特征之間的關(guān)系,并取相應(yīng)胃癌癌旁組織49例和同期正常胃粘膜組織標(biāo)本19例作為對(duì)照組,隨訪患者并進(jìn)行生存和預(yù)后分析。結(jié)果:1.采用IHC方法檢測(cè)RhoA在人胃癌組織的表達(dá),RhoA在胃癌組織、相應(yīng)癌旁組織、對(duì)照組中陽(yáng)性率分別是71.9%(64/89)、46.9%(23/49)和26.3%(5/19)。RhoA在胃癌組織與癌旁組織間、胃癌組織與正常胃粘膜組織間的陽(yáng)性率差別有統(tǒng)計(jì)學(xué)意義(P0.05),癌旁與正常胃組織的陽(yáng)性率差別無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。2.RhoA的表達(dá)與胃癌的分化程度、有無(wú)淋巴結(jié)轉(zhuǎn)移、TNM分期及Lauren分型有相關(guān)性(P0.05),與年齡、性別、腫瘤直徑大小無(wú)相關(guān)性。3.隨訪時(shí)間為12-60月,胃癌患者術(shù)后平均生存期為29.5±1.1個(gè)月,RhoA表達(dá)陽(yáng)性患者的平均生存期為27.7±1.2個(gè)月,RhoA表達(dá)陰性的患者平均生存期為33.6±2.1個(gè)月,經(jīng)Log-rank檢驗(yàn)兩者的生存期有明顯差異(P0.05),RhoA陽(yáng)性表達(dá)的生存期明顯低于RhoA陰性表達(dá)的生存期。腸型胃癌的平均生存期為32.8±1.8個(gè)月,彌漫型胃癌的平均生存期為26.4±1.5個(gè)月,混合型胃癌的平均生存期為28.6±2.6個(gè)月,經(jīng)Log-rank檢驗(yàn)三者的生存期有明顯差異(P0.05),彌漫型胃癌患者的生存期明顯低于腸型胃癌患者的生存期,混合型胃癌的生存期居于兩者之間。在腸型胃癌患者RhoA表達(dá)陽(yáng)性的患者平均總生存期為29.6±2.1個(gè)月,RhoA表達(dá)陰性的患者平均總生存期為36.6±2.8個(gè)月(P0.05);在彌漫型胃癌患者中RhoA表達(dá)陽(yáng)性的患者平均總生存期為25.3±1.7個(gè)月,RhoA表達(dá)陰性的患者平均總生存期為30.3±3.1個(gè)月(P0.05);同樣,經(jīng)Log-rank檢驗(yàn),低分化、有淋巴結(jié)轉(zhuǎn)移和TNM分期Ⅲ+Ⅳ期的胃癌患者平均生存期低于高+中分化、無(wú)淋巴結(jié)轉(zhuǎn)移和TNM分期Ⅰ+Ⅱ期的患者(p0.05),不同性別、不同年齡分段,不同腫瘤直徑大小的患者平均生存期之間無(wú)顯著性差異(p0.05),平均生存期接近。表明RhoA表達(dá)與否,勞倫分型,分化程度,淋巴結(jié)轉(zhuǎn)移、TNM分期對(duì)胃癌患者的生存期有顯著的影響,影響患者的預(yù)后。結(jié)論:RhoA在胃癌組織中高表達(dá),與腫瘤的侵襲和轉(zhuǎn)移能力有關(guān),影響胃癌患者的生存及預(yù)后,RhoA檢測(cè)有望成為新的作用靶點(diǎn),減少化療耐藥。
[Abstract]:Objective: to detect the expression of RhoA in gastric cancer tissues, analyze its expression and its significance, and analyze the survival of GCCs with follow-up data. To investigate the relationship between RhoA and prognosis and survival of GC patients. Methods: 89 paraffin specimens of gastric cancer tissues were collected from affiliated Hospital of Shandong Academy of Medical Sciences, and the expression of RhoA in gastric cancer was detected by immunohistochemical method. To analyze the relationship between the expression of RhoA and clinicopathological features, 49 cases of adjacent tissues of gastric cancer and 19 cases of normal gastric mucosa were taken as control group. The survival and prognosis of the patients were followed up. Results 1. The positive rates of RhoA expression in gastric cancer tissues and adjacent tissues were 71.9% and 46.9%, respectively. The positive rates of RIA and 26.3%(5/19).RhoA in gastric cancer tissues and adjacent tissues were 71.9% and 71.9%, respectively, and the positive rates of 26.3%(5/19).RhoA in gastric cancer tissues and adjacent tissues were 71.9% and 71.9%, respectively. There was significant difference in the positive rate between gastric cancer and normal gastric mucosa (P 0.05). There was no significant difference between adjacent gastric cancer and normal gastric tissue. 2. RhoA expression and differentiation of gastric cancer. There was no correlation between TNM staging and Lauren classification with or without lymph node metastasis. There was no correlation between TNM staging and age, sex and tumor diameter. The follow-up time was 12 to 60 months. The average survival time of patients with positive expression of RhoA was 27.7 鹵1.2 months, and the average survival time of patients with negative expression of RhoA was 33.6 鹵2.1 months. There was a significant difference in survival time between the two groups by Log-rank test. The average survival time of intestinal type gastric cancer was 32.8 鹵1.8 months, and that of diffuse gastric carcinoma was 26.4 鹵1.5 months. The average survival time of mixed gastric cancer was 28.6 鹵2.6 months. There was a significant difference among the three groups by Log-rank test. The survival time of diffuse type gastric cancer patients was significantly lower than that of intestinal type gastric cancer patients. The average total survival time of mixed gastric cancer patients with positive RhoA expression was 29.6 鹵2.1 months, the average total survival time of patients with negative RhoA expression was 36.6 鹵2.8 months (P 0.05) and that of diffuse gastric cancer patients with RhoA was 36.6 鹵2.8 months. The average total survival time of the patients with positive expression of RhoA was 25.3 鹵1.7 months. The average total survival time of the patients with negative expression of RhoA was 30.3 鹵3.1 months. By Log-rank test, the average survival time of patients with poorly differentiated gastric cancer with lymph node metastasis and TNM stage 鈪，

本文編號(hào)：1696402